D.E. Shaw & Co
TRML

D.E. Shaw & Co’s Tourmaline Bio TRML Stock Holding History

D.E. Shaw & Co’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,499
Closed -$339K – 5725
2021
Q3 		$339K Sell
2,499
-1,405
-36% -$192K ﹤0.01% 4293
2021
Q2 		$573K Buy
+3,904
New +$598K ﹤0.01% 3963

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

D.E. Shaw & Co's TRML Position: Q4 2021 in Review

D.E. Shaw & Co sold out of Tourmaline Bio (TRML) in Q4 2021, closing a stake of 2,499 shares — an estimated $339K sold.

D.E. Shaw & Co first reported a position in TRML in Q2 2021 and held it in 2 quarters. The position peaked at $573K in Q2 2021. 51 funds tracked by Wall St. Rank hold TRML as of Q4 2021.

  • D.E. Shaw & Co reported no remaining Tourmaline Bio position as of Q4 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 2,499 Tourmaline Bio shares in Q4 2021, an estimated $339K.
  • D.E. Shaw & Co first reported a position in Tourmaline Bio in Q2 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Tourmaline Bio position peaked at $573K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.